Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds have invested in a seed-funding round for Swiss biotech start-up Amal Therapeutics.
Deal will be the second add-on acquisition for Danoffice since Agilitas's buyout of the company in November 2017
Bowmark will provide additional funding of £100m to fund the company's add-ons acquisitions
Exit represents an 18x return on Octopus's initial investment and a 9x return on its total investment
Deal follows M&A litigation initiated after coronavirus uncertainty and financing difficulties